Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers

• Main Authors: Xin Jiang (Author), Pingping Lin (Author), Feifei Sun (Author), Yi Xu (Author), Ye Tao (Author), Ping Shi (Author), Yanping Liu (Author), Xin Li (Author), Shuqin Liu (Author), Xiaomeng Gao (Author), Chenjing Wang (Author), Yu Cao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: VDJ001 is a novel recombinant humanized monoclonal antibody against the anti-interleukin-6 receptor. As an analog of tocilizumab, it exhibited improved affinity and in vitro activity. Based on preclinical studies, a first-in-human clinical study was conducted to evaluate the safety, tolerabilit...